New adult supplement combines 26 vitamins, minerals and botanicals to address stress, energy, immunity and cognitive wellness in one daily tablet
Final approval for diabetes and heart-failure drug opens access to a $10.5 billion US market opportunity, with shared exclusivity benefits.
As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
The drug meets all primary endpoints across 608 patients in Europe and India, strengthening the company's biosimilars pipeline
Recognition across subsidiaries and geographies highlights pharma major’s focus on inclusive culture, employee experience, and global workforce development
Searches for diabetes, heart conditions, and metabolism-related risks are rising sharply, with Tier 2 cities outpacing metros in specialist consultations
With more than two decades of experience, he brings deep expertise in sales, marketing, business transformation, and strategic leadership
They also differentiated the innovator biologic Semaglutide molecule from newer synthetic or chemical generic versions entering the market
Move aligns global biologics identity under the Biocon Biologics brand
In his new role, Saran will spearhead the end-to-end launch framework for innovation-led portfolio
Subscribe To Our Newsletter & Stay Updated
